Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) announced results from the Phase 3 PATINA trial. The trial ...

The future of breast cancer screening and risk-reducing strategies is being shaped by artificial intelligence (AI), according ...

Research by Cancer Center genetic epidemiologist Burcu Darst, PhD, and scientists from the Canary Prostate Active ...

B reast cancer is not a single disease but multiple ones, each carrying varying degrees of risk for endangering women’s ...

A HER2-positive status reflects breast cancer cells with extra copies of the HER2 gene, or higher expression of HER2 proteins ...

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Data Safety Monitoring Board ...

Heartbreakingly, Halpin was diagnosed with multiple in her spine, lungs, ribs and both breasts. She's been told that she has metastatic breast cancer cancer is in stage 4 and is terminal.

Pfizer, facing increasing pressure from Novartis, is touting a Phase III win for Ibrance as the first clinical evidence supporting the CDK4/6 inhibitor class’ use in patients with a specific type of ...

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first ...

Adding pyrotinib to trastuzumab and docetaxel prolonged progression-free survival in patients with HER2-positive metastatic breast cancer.

Data from a late-stage study shows that LLY's experimental oral drug benefited certain breast cancer patients when used as ...

Palbociclib plus ET improved outcomes over chemotherapy ± ET maintenance in patients with high-risk, HR+, HER2- metastatic breast cancer.